{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:17:45Z","timestamp":1788254265581,"version":"build-2803163510"},"reference-count":88,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Valneva"},{"id":[{"id":"https:\/\/ror.org\/039baqv34","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Chikungunya virus (CHIKV) is a mosquito-borne alphavirus transmitted predominantly by Aedes aegypti and Aedes albopictus. Infection is characterized by an acute febrile illness accompanied by debilitating polyarthralgia, myalgia, and cutaneous manifestations. Although the acute syndrome is usually self-limited, a substantial proportion of patients experience persistent musculoskeletal symptoms that may progress to chronic inflammatory arthritis, resulting in prolonged disability and impaired quality of life. Objective: To summarize current evidence on the epidemiology, virology, immunopathogenesis, clinical manifestations, laboratory diagnosis, prevention, and vaccine development of CHIKV, with particular emphasis on its implications for public health policy and immunization strategies in Mexico. Methods: This position paper was developed through a structured narrative review of the scientific literature. Publications indexed in PubMed, Scopus, and Embase, together with documents issued by the World Health Organization (WHO), Pan American Health Organization (PAHO), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), and European Medicines Agency (EMA), were critically reviewed. Evidence was selected according to its scientific quality and relevance to Mexico and Latin America. Because this work represents an expert consensus rather than a systematic review, no formal risk-of-bias assessment was performed. Results: CHIKV circulates through both urban and sylvatic transmission cycles and continues to expand into regions where competent mosquito vectors are established. Disease progression is driven by complex innate and adaptive immune responses, with exaggerated inflammatory activation contributing to chronic rheumatologic sequelae. Laboratory confirmation relies primarily on molecular assays during the viremic phase and serological testing thereafter. Recent advances in vaccine development\u2014including live-attenuated and virus-like particle (VLP) platforms\u2014have demonstrated favorable immunogenicity and acceptable safety profiles. However, vaccination should be considered one component of an integrated prevention strategy that also includes vector surveillance, environmental control, and rapid outbreak detection. Conclusions: Chikungunya remains an emerging global public health challenge because of its expanding geographic distribution, epidemic potential, and long-term clinical consequences. Incorporating vaccination into comprehensive arboviral control programs, together with strengthened surveillance and integrated vector management, may substantially reduce disease burden. This position paper provides evidence-based recommendations to support future chikungunya prevention and vaccination policies in Mexico.<\/jats:p>","DOI":"10.3390\/vaccines14090756","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"756","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing Chikungunya Prevention and Vaccination in Mexico: A Position Paper by the Immunization Committee of the Mexican Association of Pediatric Infectious Diseases"],"prefix":"10.3390","volume":"14","author":[{"given":"Jorge A.","family":"V\u00e1zquez-Narv\u00e1ez","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Pediatrics, Hospital \u00c1ngeles Morelia, Morelia 58350, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-1503","authenticated-orcid":false,"given":"Martha","family":"Avil\u00e9s-Robles","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Infantil de M\u00e9xico Federico G\u00f3mez, Mexico City 06720, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1315-1246","authenticated-orcid":false,"given":"Carmen","family":"Espinosa-Sotero","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital General de M\u00e9xico \u201cDr. Eduardo Liceaga\u201d, Mexico City 06726, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6345-4948","authenticated-orcid":false,"given":"Cesar Adri\u00e1n","family":"Mart\u00ednez-Longoria","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Sciences, Tecnol\u00f3gico de Monterrey (TecSalud), Monterrey 64700, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbelio","family":"Moreno-Espinosa","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Department of Pediatrics, Hospital M\u00e9dica Sur, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7354-3984","authenticated-orcid":false,"given":"Monica L.","family":"Reyes-Berlanga","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Hospital MAC Irapuato, Irapuato 36520, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2466-4920","authenticated-orcid":false,"given":"Enrique","family":"Chacon-Cruz","sequence":"additional","affiliation":[{"name":"Department of Education and Research, Think Vaccines LLC, Houston, TX 77005, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rama, K., de Roo, A.M., Louwsma, T., Hofstra, H.S., Gurgel do Amaral, G.S., Vondeling, G.T., Postma, M.J., and Freriks, R.D. (2024). Clinical outcomes of chikungunya: A systematic literature review and meta-analysis. PLoS Negl. Trop. Dis., 18.","DOI":"10.1371\/journal.pntd.0012254"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1473-3099(23)00810-1","article-title":"Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: A systematic review, meta-analysis, and modelling study","volume":"24","author":"Kang","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","unstructured":"World Health Organization (2024). Chikungunya Fact Sheet, WHO. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chikungunya."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: A double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"ref_5","unstructured":"Pan American Health Organization (2026, May 13). Chikungunya: Epidemiological Update in the Americas, Available online: https:\/\/www.paho.org\/sites\/default\/files\/2023-06\/2023-jun-phe-update-arbovirus-eng.pdf."},{"key":"ref_6","unstructured":"Centers for Disease Control and Prevention (2026, May 13). Chikungunya Vaccine: Clinical Guidance for Healthcare Providers, Available online: https:\/\/www.cdc.gov\/chikungunya\/hcp\/vaccines\/index.html."},{"key":"ref_7","unstructured":"U.S. Food and Drug Administration (2026, May 13). FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(11)60281-X","article-title":"Chikungunya: A re-emerging virus","volume":"379","author":"Burt","year":"2012","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: Gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.xcrm.2025.102134","article-title":"Chikungunya virus-specific CD4+ T cells are associated with chronic chikungunya viral arthritic disease in humans","volume":"6","author":"Agarwal","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1128\/jvi.66.12.7560-7564.1992","article-title":"Alphavirus assembly and entry: Role of the cytoplasmic tail of the E1 spike subunit","volume":"66","author":"Barth","year":"1992","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya virus and the global spread of a mosquito-borne disease","volume":"372","author":"Weaver","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-018-0121-3","article-title":"Mxra8 is a receptor for multiple arthritogenic alphaviruses","volume":"557","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"199703","DOI":"10.1016\/j.virusres.2026.199703","article-title":"Overview of chikungunya virus pathogenesis, genome variation, epidemiology, and control","volume":"366","author":"Hamrahjoo","year":"2026","journal-title":"Virus Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"882","DOI":"10.4269\/ajtmh.13-0403","article-title":"Incubation periods of mosquito-borne viral infections: A systematic review","volume":"90","author":"Rudolph","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/vbz.2014.1710","article-title":"Chikungunya virus pathogenesis and immunity","volume":"15","author":"Gasque","year":"2015","journal-title":"Vector-Borne Zoonotic Dis."},{"key":"ref_17","first-page":"11939","article-title":"Chikungunya virus infection of lymphoid tissue and persistence","volume":"81","author":"Sourisseau","year":"2007","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tian, J., Li, Y., Zhao, Y., and Tao, X. (2026). Visualized analysis of core themes and emerging frontiers in global chikungunya virus studies. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1707833"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Oliveira-Neto, J.T., Souza, J.P., Rodrigues, D., Machado, M.R., Alves, J.V., Barros, P.R., Bressan, A.F., Silva, J.F., Costa, T.J., and Costa, R.M. (2024). Acute chikungunya infection induces vascular dysfunction by directly disrupting redox signaling in endothelial cells. Cells, 13.","DOI":"10.3390\/cells13211770"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.chom.2024.02.011","article-title":"Pathophysiology of chikungunya virus infection associated with fatal outcomes","volume":"32","author":"Fumagalli","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.antiviral.2013.06.009","article-title":"Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy","volume":"99","author":"Thiberville","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1099\/vir.0.82858-0","article-title":"Changing patterns of chikungunya virus: Re-emergence of a zoonotic arbovirus","volume":"88","author":"Powers","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_23","unstructured":"Pan American Health Organization, and World Health Organization (2025). Epidemiological Alert: Chikungunya and Oropouche in the Americas Region, 28 August 2025."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30234","DOI":"10.2807\/1560-7917.ES.2016.21.20.30234","article-title":"Global distribution and environmental suitability for chikungunya virus, 1952 to 2015","volume":"21","author":"Nsoesie","year":"2016","journal-title":"Eurosurveillance"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4269\/ajtmh.2008.78.333","article-title":"Seroprevalence of Chikungunya virus infection on Lamu Island, Kenya, October 2004","volume":"78","author":"Sergon","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_26","first-page":"3260","article-title":"An outbreak of chikungunya fever in the province of Ravenna, Italy","volume":"12","author":"Angelini","year":"2007","journal-title":"Eurosurveillance"},{"key":"ref_27","unstructured":"World Health Organization (2025). Chikungunya Epidemiology Update\u2014June 2025, WHO."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gutierrez, B., da Silva Candido, D., Bajaj, S., Rodriguez Maldonado, A.P., Ayala, F.G., Rodriguez, M.d.l.L.T., Rodriguez, A.A., Ar\u00e1mbula, C.W., Gonz\u00e1lez, E.R., and Mart\u00ednez, I.L. (2023). Convergent trends and spatiotemporal patterns of Aedes-borne arboviruses in Mexico and Central America. PLoS Negl. Trop. Dis., 17.","DOI":"10.1371\/journal.pntd.0011169"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gonzalez-Perez, A.L., Vazquez, A., de Ory, F., Negredo, A., Plante, K.S., Plante, J.S., Palermo, P.M., Watts, D., Paz Sanchez-Seco, M., and Weaver, S.C. (2024). Outbreak of chikungunya fever in the Central Valley of Chiapas, Mexico. medRxiv.","DOI":"10.1101\/2024.10.09.24314897"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4269\/ajtmh.21-0431","article-title":"Chikungunya in Guerrero, Mexico, 2019 and evidence of gross underreporting in the region","volume":"105","author":"Tangudu","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1086\/605496","article-title":"Chikungunya fever: An epidemiological review of a re-emerging infectious disease","volume":"49","author":"Staples","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1473-3099(07)70294-3","article-title":"Clinical burden of chikungunya virus infection","volume":"8","author":"Queyriaux","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","article-title":"Chikungunya virus: An update on the biology and pathogenesis of this emerging pathogen","volume":"17","author":"Burt","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11908-011-0180-1","article-title":"Chikungunya virus infection","volume":"13","author":"Simon","year":"2011","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/517537","article-title":"Outbreak of chikungunya on Reunion Island: Early clinical and laboratory features in 157 adult patients","volume":"44","author":"Borgherini","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/ar4137","article-title":"Predictors of chikungunya rheumatism: A prognostic survey ancillary to the TELECHIK cohort study","volume":"15","author":"Fianu","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Couderc, T., Chr\u00e9tien, F., Schilte, C., Disson, O., Brigitte, M., Guivel-Benhassine, F., Touret, Y., Barau, G., Cayet, N., and Schuffenecker, I. (2008). A mouse model for chikungunya: Young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.0040029"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1017\/S0950268808001167","article-title":"Atypical chikungunya virus infections: Clinical manifestations, mortality and risk factors for severe disease during the 2005\u20132006 outbreak on R\u00e9union","volume":"137","author":"Economopoulou","year":"2009","journal-title":"Epidemiol. Infect."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"G\u00e9rardin, P., Barau, G., Michault, A., Bintner, M., Randrianaivo, H., Choker, G., Lenglet, Y., Touret, Y., Bouveret, A., and Grivard, P. (2008). Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of R\u00e9union. PLoS Med., 5.","DOI":"10.1371\/journal.pmed.0050060"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.4049\/jimmunol.0900255","article-title":"Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response","volume":"184","author":"Hoarau","year":"2010","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Javelle, E., Ribera, A., Degasne, I., Ga\u00fcz\u00e8re, B.A., Marimoutou, C., and Simon, F. (2015). Specific management of post-chikungunya rheumatic disorders: A retrospective study of 159 cases in R\u00e9union Island. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003603"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kelvin, A.A., Banner, D., Silvi, G., Moro, M.L., Spataro, N., Gaibani, P., Cavrini, F., Pierro, A., Rossini, G., and Cameron, M.J. (2011). Inflammatory cytokine expression is associated with chikungunya virus resolution and symptom severity. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001279"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1084\/jem.20090851","article-title":"Type I IFN controls chikungunya virus via its action on nonhematopoietic cells","volume":"207","author":"Schilte","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jis033","article-title":"Early appearance of neutralizing IgG3 antibodies is associated with chikungunya virus clearance and long-term clinical protection","volume":"205","author":"Kam","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ng, L.F., Chow, A., Sun, Y.J., Kwek, D.J., Lim, P.L., Dimatatac, F., Ng, L.-C., Ooi, E.-E., Choo, K.-H., and Her, Z. (2009). IL-1\u03b2, IL-6, and RANTES as biomarkers of chikungunya severity. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004261"},{"key":"ref_47","first-page":"175","article-title":"Chikungunya virus: A general overview","volume":"17","year":"2015","journal-title":"Med. Univ."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/0972-9062.353231","article-title":"Investigation of chikungunya virus genotype at tertiary care center in Western Maharashtra, India","volume":"60","author":"Suryavanshi","year":"2023","journal-title":"J. Vector Borne Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40506-018-0172-x","article-title":"Advances in clinical diagnosis and management of chikungunya virus infection","volume":"10","author":"Carrera","year":"2018","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"(2017). Chikungunya virus: Clinical aspects and treatment\u2014A review. Mem. Inst. Oswaldo Cruz., 112, 523\u2013531.","DOI":"10.1590\/0074-02760170044"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3329\/ssmcj.v32i2.84815","article-title":"Diagnosis of chikungunya infection: A narrative review","volume":"32","author":"Khan","year":"2025","journal-title":"Sir Salimullah Med. Coll. J."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Andrew, A., Navien, T., Yeoh, T., Citartan, M., Mangantig, E., Sum, M., Ch\u2019ng, E.S., and Tang, T.-H. (2022). Diagnostic accuracy of serological tests for the diagnosis of chikungunya virus infection: A systematic review and meta-analysis. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010152"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/CVI.05288-11","article-title":"Poor diagnostic accuracy of commercial antibody-based assays for the diagnosis of acute chikungunya infection","volume":"18","author":"Blacksell","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2396484","DOI":"10.1080\/21505594.2024.2396484","article-title":"Pathogenicity and virulence of chikungunya virus","volume":"15","author":"Freppel","year":"2024","journal-title":"Virulence"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"101672","DOI":"10.1016\/j.eclinm.2022.101672","article-title":"An evaluation of global chikungunya clinical management guidelines: A systematic review","volume":"54","author":"Webb","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"23997","DOI":"10.1038\/srep23997","article-title":"Evaluating the effectiveness of localized control strategies to curtail chikungunya","volume":"6","author":"Durham","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Monteiro, V., Navegantes-Lima, K., Lemos, A., Silva, G., Souza Gomes, R., Reis, J.F., Junior, L.R., Da Silva, O.S., Rom\u00e3o, P.R.T., and Monteiro, M.C. (2019). Aedes\u2013chikungunya virus interaction: Key role of vector midguts microbiota and its saliva in the host infection. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00492"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.21608\/jesp.2023.331733","article-title":"Chikungunya virus versus Aedes-borne other viruses: A review article","volume":"53","author":"Morsy","year":"2023","journal-title":"J. Egypt. Soc. Parasitol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s43856-022-00192-7","article-title":"Spatio-temporal dynamics of three diseases caused by Aedes-borne arboviruses in Mexico","volume":"2","author":"Dong","year":"2022","journal-title":"Commun. Med."},{"key":"ref_60","first-page":"267","article-title":"Paradoxical effect of antibodies in chikungunya virus disease","volume":"15","author":"Roques","year":"2017","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_61","unstructured":"Teo, T.H., Her, Z., Tan, J.J., Lum, F.M., Lee, W.W., Chan, Y.H., Ong, R.Y., Kam, Y.W., Leparc-Goffart, I., and Gallian, P. (2015). Caribbean and Latin American outbreak strains of chikungunya virus differ in virulence in a mouse model. PLoS Negl. Trop. Dis., 9."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: Epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11644","DOI":"10.1128\/JVI.01432-14","article-title":"Reemergence of chikungunya virus","volume":"88","author":"Morrison","year":"2014","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijid.2017.03.006","article-title":"Global expansion of chikungunya virus: Mapping the 21st-century epidemic","volume":"58","author":"Wahid","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.idc.2019.08.006","article-title":"Chikungunya: Epidemiology, pathogenesis, clinical features, management, and prevention","volume":"33","author":"Vairo","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3201\/eid1206.051210","article-title":"Dengue prevention and 35 years of vector control in Singapore","volume":"12","author":"Ooi","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e00116","DOI":"10.1016\/j.parepi.2019.e00116","article-title":"Environmental suitability for Aedes aegypti and Aedes albopictus and the spatial distribution of major arboviral infections in Mexico","volume":"6","author":"Lubinda","year":"2019","journal-title":"Parasite Epidemiol. Control"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13071-016-1403-y","article-title":"Forecasting Chikungunya spread in the Americas via data-driven empirical approaches","volume":"9","author":"Escobar","year":"2016","journal-title":"Parasites Vectors"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"taae123","DOI":"10.1093\/jtm\/taae123","article-title":"From bench to clinic: The development of VLA1553\/IXCHIQ, a live-attenuated chikungunya vaccine","volume":"31","author":"Chen","year":"2024","journal-title":"J. Travel Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"The Lancet Infectious Diseases (2025). More data needed on the FDA\u2019s decision to suspend Ixchiq. Lancet Infect. Dis., 25, 1055.","DOI":"10.1016\/S1473-3099(25)00552-3"},{"key":"ref_71","unstructured":"Monaco Times (2025). Chikungunya Epidemic in La R\u00e9union Marks Twelve Deaths in 2025, Monaco Times."},{"key":"ref_72","unstructured":"Centers for Disease Control and Prevention (2026). Chikungunya Vaccine Information for Healthcare Providers."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Maurer, G., Buerger, V., Larcher-Senn, J., Erlsbacher, F., Meyer, S., Eder-Lingelbach, S., and Jaramillo, J.C. (2025). Comprehensive assessment of reactogenicity and safety of the live-attenuated chikungunya vaccine (IXCHIQ\u00ae). Vaccines, 13.","DOI":"10.3390\/vaccines13060576"},{"key":"ref_74","unstructured":"European Medicines Agency (2026, May 13). Ixchiq: Temporary Restriction on Vaccinating People 65 Years and Older to Be Lifted. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted."},{"key":"ref_75","unstructured":"Public Health Agency of Canada, and Committee to Advise on Tropical Medicine and Travel (CATMAT) (2026, May 13). Recommendations for the Use of Chikungunya Live Attenuated Vaccine (IXCHIQ), Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/catmat\/recommendations-use-chikungunya-vaccine.html."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(25)00345-9","article-title":"CBSI-CV-317-004 Study Group. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: A phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Richardson","year":"2025","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(25)00372-1","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: A phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Tindale","year":"2025","journal-title":"Lancet"},{"key":"ref_78","unstructured":"Medicines and Healthcare Products Regulatory Agency (2026, May 13). IXCHIQ Vaccine Approved to Protect Adults Against Chikungunya, Available online: https:\/\/www.gov.uk\/government\/news\/ixchiq-vaccine-approved-to-protect-adults-against-chikungunya."},{"key":"ref_79","unstructured":"European Medicines Agency (2025). Ixchiq-Referral, EMA. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/ixchiq."},{"key":"ref_80","unstructured":"U.S. Food and Drug Administration (2026, May 13). FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live): FDA Safety Communication, Available online: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-safety-communication."},{"key":"ref_81","unstructured":"U.S. Food and Drug Administration (2026, May 13). FDA Update on the Safety of IXCHIQ (Chikungunya Vaccine, Live): FDA Suspends Biologics License, Available online: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-suspends-biologics-license-fda-safety."},{"key":"ref_82","unstructured":"Outbreak News Today (2025). Valneva to Provide 40,000 IXCHIQ Chikungunya Vaccine Doses."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/vbz.2014.1681","article-title":"Therapeutics and vaccines against chikungunya virus","volume":"15","author":"Ahola","year":"2015","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref_84","unstructured":"European Medicines Agency (2025). Vimkunya, EMA."},{"key":"ref_85","unstructured":"Valneva, S.E. (2026). Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ\u00ae, Valneva."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12026-012-8266-x","article-title":"Mouse models for chikungunya virus: Deciphering immune mechanisms responsible for disease and protection","volume":"53","author":"Teo","year":"2012","journal-title":"Immunol. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1172\/JCI63120","article-title":"Viperin restricts chikungunya virus replication and pathology","volume":"122","author":"Teng","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/infdis\/jiq042","article-title":"Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor","volume":"203","author":"Chow","year":"2011","journal-title":"J. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/756\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:44:10Z","timestamp":1788252250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":88,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090756"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090756","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}